Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care
Use of GL-ONC1 in Patients With Advanced Cancers With No Standard of Care
Sponsor: Genelux Corporation
A observational or N/A phase clinical study on Acute Myeloid Leukemia (6 Patients) and Advanced Stage Cancer (Solid Tumor Disease for 4 Patients), this trial is ongoing. The trial is conducted by Genelux Corporation and has accumulated 8 data snapshots since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Oct 2024 — Present [monthly]
No Longer Available
Status: Temporarily Not Available → No Longer Available
-
Sep 2024 — Oct 2024 [monthly]
Temporarily Not Available
-
Jul 2024 — Sep 2024 [monthly]
Temporarily Not Available
-
Aug 2023 — Jul 2024 [monthly]
Temporarily Not Available
Status: No Longer Available → Temporarily Not Available
-
Jan 2021 — Aug 2023 [monthly]
No Longer Available
▶ Show 3 earlier versions
-
Sep 2019 — Jan 2021 [monthly]
No Longer Available
Status: Available → No Longer Available
-
Apr 2018 — Sep 2019 [monthly]
Available
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Available NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Genelux Corporation
For direct contact, visit the study record on ClinicalTrials.gov .